[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mucositis-oral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mucositis-oral":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100563987","a-clinical-trial-of-the-administration-of-light-therapy-to-prevent-mouth-sores-in-children-with-cancer-100563987",false,"NCT06623305","A Clinical Trial of the Administration of Light Therapy to Prevent Mouth Sores in Children With Cancer","Photobiomodulation Therapy for the Prevention of Mucositis in Pediatric Oncology Patients","PBM","Inclusion Criteria:\n\n1. Current and new diagnosis patients consented upon admission if deemed eligible\n2. Ages 0-30\n3. Admitted to CW oncology\u002FBMT inpatient unit, PICU, or West 5\n4. Chemotherapy regimen: Methotrexate ≥5 g\u002Fm2 (or ≥1 g\u002Fm2 if Trisomy 21) OR Anthracycline ≥60 mg\u002Fm2\n5. Able to speak and understand English or Spanish\n\nExclusion Criteria:\n\n1. Patients admitted on BMT service\n2. Patients currently experiencing mucositis with a CTCAE grade 4 oral mucositis or higher","ALL","30 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if light therapy can prevent mouth sores in children with cancer. The main questions it aims to answer are:\n\nIs it reasonable and acceptable to provide light therapy for children with cancer?\n\nDoes light therapy prevent mouth sores related to medical treatment?\n\nResearchers will compare children who do not receive light therapy to children who do receive light therapy during the clinical trial to see if light therapy helps to prevent mucositis.\n\nParticipants will:\n\n* Complete a survey.\n* Have picture taken of their mouth to look for mouth sores.\n* Receive light therapy every day while admitted to the hospital on the cancer unit or while admitted to an alternate unit, and continue to receive light therapy in the home setting until they reach 8 days after the start of their chemotherapy cycle.",[27],"Mucositis Oral",[29,30,31],"Photobiomodulation","Mucositis","Oral Mucositis","NOT_YET_RECRUITING","2026-06-16",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":21},"2026-08",{"date":40,"type":21},"2027-09",{"name":42,"class":43},"Medical College of Wisconsin","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100641380","music-therapy-for-oral-mucositis-pain-in-pediatric-patients-100641380","NCT07653360","Music Therapy for Oral Mucositis Pain in Pediatric Patients","Effect of Music Therapy on Oral Mucositis Pain in Pediatric Patients","Inclusion Criteria:\n\nPhase 1\n\n* Child ages 6-18 years old\n* Child has received music therapy and experienced oral mucositis\n* Parent\u002Fguardian 18 years and older\n* Able to communicate in English\n\nExclusion Criteria:\n\nPhase 1\n\n* Diagnosis of a developmental disorder that would prevent engagement in the active music-making or passive music-listening intervention or completion of study measures.\n* Significant pre-existing hearing loss or impairment that would interfere with participation in the interventions.",true,"6 Years","64 Years",{"count":20,"type":21},[24],"This mixed-methods pilot study will examine the effect of music therapy on oral mucositis pain in pediatric oncology patients. Oral mucositis, characterized by painful ulcerative lesions in the mouth, is a common side effect of high-dose chemotherapy and hematopoietic stem cell or bone marrow transplantation. Despite its high prevalence and impact on quality of life, effective pain management strategies for pediatric oral mucositis remain limited and often rely heavily on medications that may cause significant side effects or provide insufficient relief. Music therapy may offer a promising non-pharmacologic adjunct for reducing pain, yet no studies to date have specifically evaluated its use for oral mucositis pain in pediatric patients.",[59,60,27],"Oral Mucosa Discomfort","Pediatric Cancer",[62],"Music Therapy","2026-06-11",{"date":65,"type":36},"2026-06-17",{"date":67,"type":21},"2026-07-01",{"date":69,"type":21},"2027-05-31",{"name":71,"class":43},"University of California, San Francisco",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":44},"100607031","using-red-light-therapy-to-ease-skin-side-effects-and-mouth-side-effects-in-children-and-young-people-aged-0-to-16-years-old-receiving-radiotherapy-100607031","NCT07183267","Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Years Old, Receiving Radiotherapy","Reducing rAdiation aDverse Effects of dermatitIs and mucosAl inflammatioN Using Red Light Therapy","RADIANT","Inclusion Criteria:\n\n* Paediatric patient receiving a treatment course of either proton or photon therapy - Craniospinal treatment field, Head and Neck treatment fields and body treatment fields.\n\nExclusion Criteria:\n\n* Paediatric patients receiving focal brain only proton or photon radiotherapy.\n* Paediatric patients receiving a single fraction of proton or photon therapy.\n* Total Body Irradiation patients.","0 Years","16 Years",{"count":83,"type":21},248,[24],"The goal of this interventional study is to see if the daily use of red light therapy called photobiomodulation can help sore skin and sore mouths in children having radiotherapy.\n\nAll children aged 0-16 years old who are receiving either proton or photon radiotherapy treatment, except to the brain only, will be asked if they would like to join the study.\n\nThe main questions it aims to answer are:\n\n1. Does the use of red light therapy help the skin side effects in children and young people undergoing proton or photon therapy?\n2. Does the use of red light therapy help the mouth side effects in children and young people undergoing proton or photon therapy in the head and neck area?\n\nResearchers will compare the patients enrolled on to the study with a like for like historic patient to see if red light therapy improves the sore skin and sore mouths caused by proton or photon therapy.\n\nParticipants will have a daily treatment with red light therapy alongside their daily proton or photon treatment fraction.",[87,27,88],"Radio Dermatitis","Oesophagitis",[90,91,92,93,94],"Paediatric skin toxicity","paediatric oral mucositis","paediatric proton therapy","paediatric radiotherapy","paediatric photon therapy","2026-03-17",{"date":97,"type":36},"2026-03-19",{"date":99,"type":21},"2026-06-01",{"date":101,"type":21},"2028-10-01",{"name":103,"class":43},"The Christie NHS Foundation Trust",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100361224","phase-3-low-level-laser-therapy-in-the-prevention-of-chemotherapy-induced-mucositis-in-children-and-young-adults-100361224","NCT03983369","Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults","Multicenter Double Blind Randomized Placebo-controlled Trial Assessing the Efficacy of Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults","MUCILA","Inclusion Criteria:\n\n1. Age \\> 4 and ≤ 25 years\n2. No mucositis or other mouth lesions at the beginning of chemotherapy that could prevent the laser session and chemotherapy\n3. Cooperative patient, able to wear black glasses and to sit with his open mouth during laser session\n4. Patients treated in one of the SFCE centers that participate to the study\n5. Patients undergoing chemotherapy course with high risk of severe mucositis :\n\n   1. high-dose chemotherapy with hematological stem cell transplantation (stratum A) including but not limited to 8 HDC conditioning regimens for solid tumors intensive treatment (Busilvex-Melphalan, VP16-Thiotepa, BAM, BEAM, Thiotepa 900mg\u002Fm\\^2, Carboplatine-Thiotepa (typical teratoid rhabdoid tumor or medulloblastoma), VP16-Carboplatine-Thiotepa, Endoxan-Busilvex and VP16 - Melphalan) and 5 myeloablative conditioning regimens (for example : TBI-VP16, Busilvex-Endoxan-Thiotepa, Busilvex-Endoxan+\u002F-Melphalan and Thiotepa-Busulfan-Fludarabine),\n   2. Conventional chemotherapy courses (stratum B) but not limited to COPADM (B lymphoma), CAV\u002FICE (plexus choroid carcinoma or B lymphoma), Head start induction course (medulloblastoma), N6 course (neuroblastoma), VIDE or VCD (Ewing sarcoma), API\u002FAP (osteosarcoma), Cyclophosphamide and Doxorubicine (nephroblastoma), PLADO\u002FCarboplatine and Doxorubicine (hepatoblastoma), IVADo (rhabdomyosarcoma), induction and consolidation of the Myechild protocol (Cytarabine\u002FMithoxantrone Fludarabine Aractine +\u002F- Darubicine) (acute myeloid leukemia) and 5FU-cisplatine (undifferentiated carcinoma of nasopharyngeal),\n   3. Others courses of chemotherapy (stratum A or B) which may cause mucositis can be considered (please refer to the non-inclusion criterion n° 5 to see the prohibited chemotherapy list). In this case, the coordinating investigator approval is required.\n6. Women of childbearing potential must have a negative serum β-HCG pregnancy test prior to the administration of the first laser treatment.\n7. French speaking patients\n8. Patient and\u002For parents\u002Flegal representatives should understand, sign, and date the written informed consent form prior to any protocol specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.\n9. Patients must be affiliated to a social security regimen or beneficiary of the same\n\nNB : all patients who respect all the eligibility criteria are recruitable even if the patient haven't a cancer (Patients undergoing a chemotherapy with high risk of severe mucositis for another clinical reason than cancer).\n\nExclusion Criteria:\n\n1. Treatment by opioids on daily basis\n2. Orthodontic appliance\n3. Pregnant or breastfeeding young ladies or women\n4. Patients with cognitive disorder who could not self-evaluate his pain or with a mucositis difficult to evaluate\n5. None of this chemotherapy is allowed : Methotrexate, VA or VAD (nephroblastoma), Carboplatine - Etoposide (3 or 5 days), Temozolomide single agent or in combination with Topotecan\u002FIrinotecan or Bevacizumab, Gemzar, Taxotere, Ifosfamide - Etoposide (Ewing sarcoma), OEPA, COPDAC, IgEV (Hodgkin lymphoma)","4 Years","25 Years",{"count":115,"type":21},315,[117],"PHASE3","To assess the efficacy of preventive Low-Level Laser Therapy (LLLT) for reducing the incidence of WHO's grade 3-4 oral mucositis in children and young adults receiving chemotherapy regimens associated with a high rate of mucositis: conventional chemotherapy or High Dose Chemotherapy (HDC) conditioning regimens with Hematological Stem Cell Transplantation (HSCT).",[27],"RECRUITING","2026-02-05",{"date":123,"type":36},"2026-02-06",{"date":125,"type":36},"2018-08-29",{"date":127,"type":21},"2026-09",{"name":129,"class":43},"Gustave Roussy, Cancer Campus, Grand Paris",5]